{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:30:19Z","timestamp":1776468619219,"version":"3.51.2"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.pharmthera.2016.03.008","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T08:52:00Z","timestamp":1458636720000},"page":"118-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pharmacological approaches of refractory angina"],"prefix":"10.1016","volume":"163","author":[{"given":"Andreas A.","family":"Giannopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Giannoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiannis S.","family":"Chatzizisis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.03.008_bb0005","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0140-6736(96)08359-6","article-title":"Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients","volume":"349","author":"Alderman","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0010","article-title":"Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: Results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial","author":"Alexander","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","article-title":"Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease","volume":"64","author":"Andersson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijcard.2009.09.538","article-title":"Fatality, morbidity and quality of life in patients with refractory angina pectoris","volume":"147","author":"Andr\u00e9ll","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0030","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(10)60578-8","article-title":"Allopurinol for chronic stable angina: old drug, new tricks?","volume":"375","author":"Antony","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ahj.2015.07.025","article-title":"Glucose-lowering medications and angina burden in patients with stable coronary disease: Results from the type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina (TERISA) trial","volume":"170","author":"Arnold","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0040","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0735-1097(99)00140-0","article-title":"The multicenter study of enhanced external counterpulsation (MUST-EECP): Effect of EECP on exercise-induced myocardial ischemia and anginal episodes","volume":"33","author":"Arora","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1527-3466.2007.00006.x","article-title":"Perhexiline","volume":"25","author":"Ashrafian","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0050","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.jacc.2007.01.061","article-title":"Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: A prospective, open-label, multicenter, safety feasibility first-in-man study","volume":"49","author":"Banai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0055","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1136\/hrt.2005.078790","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0065","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0070","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003712.pub3","article-title":"Transmyocardial laser revascularization versus medical therapy for refractory angina","volume":"2","author":"Briones","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM197212142872401","article-title":"Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases","volume":"287","author":"Buhler","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0085","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb9000","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0095","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00045391-200501000-00006","article-title":"Trimetazidine in angina combination therapy\u2014the TACT study: Trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study","volume":"12","author":"Chazov","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9149(02)02664-4","article-title":"Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X","volume":"90","author":"Chen","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0110","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003614.pub2","article-title":"Trimetazidine for stable angina","author":"Ciapponi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0120","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/01.CIR.81.4.1260","article-title":"Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent","volume":"81","author":"Cole","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","article-title":"Coronary microvascular dysfunction: An update","volume":"35","author":"Crea","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2015.03.150","article-title":"The effectiveness of intensive medical treatment in patients initially diagnosed with refractory angina","volume":"186","author":"Dourado","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0135","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/eurheartj\/ehv150","article-title":"The role of heart rate may differ according to pathophysiological setting: From SHIFT to SIGNIFY","volume":"36","author":"Ferrari","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0140","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0145","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0155","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.yjmcc.2006.08.012","article-title":"Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts","volume":"41","author":"Fraser","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0160","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0735-1097(02)02848-6","volume":"41","author":"Gibbons","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0170","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of beta-blocker dose on survival after acute myocardial infarction","volume":"66","author":"Goldberger","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2016.03.008_bb0175","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00005344-199206203-00006","article-title":"Cardioprotective effects of nicorandil","volume":"20","author":"Gross","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0180","article-title":"Coronary artery disease: A dam in the river for ranolazine","author":"Head","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0185","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","article-title":"Meta-analysis of trials comparing \u03b2-blockers, calcium antagonists, and nitrates for stable angina","volume":"281","author":"Heidenreich","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0190","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1161\/CIRCULATIONAHA.107.720953","article-title":"Prevalence of angina in women versus men","volume":"117","author":"Hemingway","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0195","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/heartjnl-2011-301436","article-title":"Management of stable angina: summary of NICE guidance","volume":"98","author":"Henderson","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0200","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0205","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrcardio.2013.200","article-title":"Treatment of refractory angina in patients not suitable for revascularization","volume":"11","author":"Henry","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0210","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0167-5273(86)90146-4","article-title":"Perhexiline maleate treatment for severe angina pectoris\u2014Correlations with pharmacokinetics","volume":"13","author":"Horowitz","year":"1986","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(15)61283-1","article-title":"Pharmacological and emerging therapies in the treatment of chronic angina","volume":"386","author":"Husted","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0225","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","article-title":"Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial","volume":"359","author":"Iona Study Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0002-9149(97)00279-8","article-title":"Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina","volume":"80","author":"Jaw-Wen","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0235","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0240","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/00005344-200012000-00016","article-title":"Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia\/reperfusion in the isolated rat heart","volume":"36","author":"Kennedy","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00129784-200101030-00005","article-title":"Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease","volume":"1","author":"Killalea","year":"2001","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0250","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1742-1241.2003.tb10632.x","article-title":"Trimetazidine in geriatric patients with stable angina pectoris: The Tiger Study","volume":"57","author":"Kolbel","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0255","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/VHRM.S11100","article-title":"Recent advances in the management of chronic stable angina. II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization","volume":"6","author":"Kones","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0260","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jacc.2006.10.067","article-title":"Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The ranolazine open label experience (ROLE)","volume":"49","author":"Koren","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0265","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: Results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2016.03.008_bb0270","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199206203-00002","article-title":"Molecular mechanism of action of nicorandil","volume":"20","author":"Kukovetz","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00129784-200707020-00006","article-title":"Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention","volume":"7","author":"Labrou","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0280","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/clc.4960240803","article-title":"Spinal cord stimulation for chronic intractable angina pectoris: A unified theory on its mechanism","volume":"24","author":"Latif","year":"2001","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-015-0682-9","article-title":"Coronary microvascular dysfunction, microvascular angina, and management","volume":"18","author":"Loffler","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0290","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/clc.20117","article-title":"Enhanced external counterpulsation in the treatment of chronic refractory angina: A long-term follow-up outcome from the international enhanced external counterpulsation patient registry","volume":"31","author":"Loh","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0295","first-page":"343","article-title":"Management of refractory angina pectoris","volume":"18","author":"Manchanda","year":"2011","journal-title":"Cardiol J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0300","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina. Report from the ESC Joint Study Group on the treatment of refractory angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0305","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jcmg.2014.12.008","article-title":"Coronary microvascular dysfunction, microvascular angina, and treatment strategies","volume":"8","author":"Marinescu","year":"2015","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0310","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0195-668X(03)00202-1","article-title":"Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil","volume":"24","author":"Matsuo","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0315","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/HYPERTENSIONAHA.106.085738","article-title":"Long-term trandolapril treatment is associated with reduced aortic stiffness","volume":"49","author":"Mitchell","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0735-1097(02)02632-3","article-title":"Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm","volume":"41","author":"Mohri","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0325","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0330","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non\u2013st-elevation acute coronary syndromes: The Merlin\u2013Timi 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0335","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial","volume":"375","author":"Noman","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0340","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ijcard.2014.10.149","article-title":"The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials","volume":"177","author":"Peng","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0345","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0002-9149(99)00190-3","article-title":"A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents","volume":"84","author":"Pepine","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0350","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/eurjhf\/hfp106","article-title":"Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: Old drug, new hope","volume":"11","author":"Phan","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0355","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001287","article-title":"Predictors of long-term clinical endpoints in patients with refractory angina","volume":"4","author":"Povsic","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0365","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjci\/jet251","article-title":"Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: Insights from SATURN","volume":"15","author":"Puri","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0370","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/14.suppl_B.35","article-title":"A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina","volume":"14","author":"Raftery","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0375","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2012.09.066","article-title":"High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease","volume":"61","author":"Rekhraj","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0380","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","article-title":"Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: A 3-month randomised, double-blind, multicentre, noninferiority trial","volume":"67","author":"Ruzyllo","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0385","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0390","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1074248415571457","article-title":"Nicorandil versus nitroglycerin for symptomatic relief of angina in patients with slow coronary flow phenomenon: A randomized clinical trial","volume":"20","author":"Sani","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0395","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00005344-200211000-00013","article-title":"Anti-anginal effect of fasudil, a rho-kinase inhibitor, in patients with stable effort angina: A multicenter study","volume":"40","author":"Shimokawa","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0400","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00878320","article-title":"A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris","volume":"7","author":"Somma","year":"1993","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0405","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11936-009-0006-8","article-title":"Treatment options for refractory angina pectoris: Enhanced external counterpulsation therapy","volume":"11","author":"Soran","year":"2009","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0410","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","article-title":"Role of ranolazine in angina, heart failure, arrhythmias, and diabetes","volume":"133","author":"Sossalla","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0415","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jacc.2011.02.072","article-title":"Allopurinol: A new anti-ischemic role for an old drug","volume":"58","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0420","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0425","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.008_bb0430","first-page":"S25","article-title":"Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: Results of three studies","volume":"12","author":"Szwed","year":"2001","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0435","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jacc.2006.03.069","article-title":"Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography","volume":"48","author":"Tahara","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0440","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0445","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2016.03.008_bb0450","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00005344-199206203-00010","article-title":"Acute hemodynamic effects of nicorandil in coronary artery disease","volume":"20","author":"Treese","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0455","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0460","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0003319714530040","article-title":"Trimetazidine and cardioprotection: Facts and perspectives","volume":"66","author":"Tsioufis","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0465","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/00005344-199206203-00012","article-title":"Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: A double-blind, randomized, multicenter study","volume":"20","author":"Ulvenstam","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0470","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJMoa1402556","article-title":"Efficacy of a device to narrow the coronary sinus in refractory angina","volume":"372","author":"Verheye","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0475","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2005.07.047","article-title":"Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial","volume":"46","author":"Vicari","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0480","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.phrs.2006.03.016","article-title":"The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease","volume":"53","author":"Vilaine","year":"2006","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0485","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","author":"Weisz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0490","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1053\/euhj.2002.3296","article-title":"Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide","volume":"23","author":"Willoughby","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0495","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1161\/CIRCRESAHA.110.231340","article-title":"Compartmentalization of beta-adrenergic signals in cardiomyocytes","volume":"109","author":"Xiang","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0500","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002002","article-title":"Efficacy of enhanced external counterpulsation in patients with chronic refractory angina on Canadian Cardiovascular Society (CCS) angina class: An updated meta-analysis","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0505","article-title":"Effect of trimetazidine in patients undergoing percutaneous coronary intervention: A meta-analysis","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.008_bb0510","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1253\/circj.71.826","article-title":"Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China","volume":"71","author":"Zhu","year":"2007","journal-title":"Circ J"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581630016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581630016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:11:14Z","timestamp":1692263474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581630016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":103,"alternative-id":["S016372581630016X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.008","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological approaches of refractory angina","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}